Biocon has informed that it has enclosed the press release on 1st march 2021 titled ‘Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.